Ironwood Pharmaceuticals, Inc. revised earnings guidance for the year 2022. For the year, the company expects total revenue of $411 million compared to previous guidance rang of $420 million - $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.12 USD | -2.17% | +3.84% | -29.02% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.02% | 1.29B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2022